High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

DISEASE CHARACTERISTICS:

* Newly confirmed diagnosis of intestinal T-cell lymphoma/ enteropathy-type T-cell lymphoma according to the following WHO classifications:

  * Usual phenotype CD3-, CD7-positive; CD5-, CD4-, CD8-negative; or CD30-positive
* Complete surgical resection allowed

PATIENT CHARACTERISTICS:

* Unsupported neutrophils ≥ 1,500/mm\^3 unless attributed to lymphomatous bone marrow infiltration
* Unsupported platelets ≥ 100,000/mm\^3 unless attributed to lymphomatous bone marrow infiltration
* Creatinine clearance ≥ 50 mL/min
* Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)
* Bilirubin ≤ 2.5 times ULN
* Left ventricular ejection fraction ≥ 50%
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment
* Patients with any serious concomitant medical or psychiatric condition that would preclude them tolerating the planned treatment should be entered into the registration study only
* No known hepatitis B, hepatitis C, or HIV positivity
* No active uncontrolled cardiovascular disease
* No abnormal EKG if there is a previous history of cardiac problems
* No other severe impairment of cardiac function
* No active malignancy within the past 5 years except cervical intraepithelial neoplasia or localized skin cancer

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior diagnostic or emergency surgical procedures allowed
* More than 5 years since prior treatment for malignancy
* No prior chemotherapy or radiotherapy for treatment of lymphoma